Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation.

carcinoma checkpoint inhibitors hepatocellular immunomodulation radiofrequency

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
23 May 2020
Historique:
received: 24 04 2020
revised: 16 05 2020
accepted: 22 05 2020
entrez: 28 5 2020
pubmed: 28 5 2020
medline: 28 5 2020
Statut: epublish

Résumé

A majority of hepatocellular carcinoma (HCC) develops in the setting of persistent chronic inflammation as immunological mechanisms have been shown to play a vital role in the initiation, growth and progression of tumours. The index review has been intended to highlight ongoing immunological changes in the hepatic parenchyma responsible for the genesis and progression of HCC. The in-situ vaccine effect of radiofrequency (RF) is through generation tumour-associated antigens (TAAs), following necrosis and apoptosis of tumour cells, which not only re-activates the antitumour immune response but can also act in synergism with checkpoint inhibitors to generate a superlative effect with intent to treat primary cancer and distant metastasis. An improved understanding of oncogenic responses of immune cells and their integration into signaling pathways of the tumour microenvironment will help in modulating the antitumour immune response. Finally, we analyzed contemporary literature and summarised the recent advances made in the field of targeted immunotherapy involving checkpoint inhibitors along with RF application with the intent to reinstate antitumour immunity and outline future directives in very early and early stages of HCC.

Identifiants

pubmed: 32456200
pii: vaccines8020247
doi: 10.3390/vaccines8020247
pmc: PMC7349974
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Cancer Biol Med. 2016 Jun;13(2):206-14
pubmed: 27458528
Nature. 2004 Nov 18;432(7015):332-7
pubmed: 15549095
Semin Liver Dis. 2014 Nov;34(4):376-88
pubmed: 25369300
Biomed Res Int. 2013;2013:187204
pubmed: 23533994
J Hepatol. 2012 Mar;56(3):704-13
pubmed: 22120206
Clin Cancer Res. 2007 Feb 1;13(3):902-11
pubmed: 17289884
World J Gastroenterol. 2014 Dec 21;20(47):18059-60
pubmed: 25548509
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700
pubmed: 26484443
Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20
pubmed: 14762851
Methods Mol Med. 2000;45:157-65
pubmed: 21341054
Nat Rev Gastroenterol Hepatol. 2018 Sep;15(9):555-567
pubmed: 29844586
Arch Toxicol. 2013 Feb;87(2):227-47
pubmed: 23007558
Hepatology. 2014 Apr;59(4):1415-26
pubmed: 24002931
Lancet Oncol. 2016 Dec;17(12):e542-e551
pubmed: 27924752
Front Oncol. 2018 Jul 13;8:269
pubmed: 30057891
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Liver Cancer. 2016 Oct;5(4):290-302
pubmed: 27781201
Ann Hepatol. 2019 Mar - Apr;18(2):291-297
pubmed: 31047849
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
Hepatology. 1998 Feb;27(2):407-14
pubmed: 9462638
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
J Hepatol. 2017 Mar;66(3):545-551
pubmed: 27816492
World J Gastroenterol. 2014 Feb 7;20(5):1268-88
pubmed: 24574801
Immunity. 2019 Feb 19;50(2):403-417.e4
pubmed: 30709740
Dig Dis. 2015 Sep;33(5):635-41
pubmed: 26398186
Immunol Rev. 2009 May;229(1):12-26
pubmed: 19426212
Cancer Cell. 2016 Aug 8;30(2):308-323
pubmed: 27478039
World J Gastroenterol. 2018 Sep 21;24(35):3974-3979
pubmed: 30254402
Semin Cancer Biol. 2011 Feb;21(1):35-43
pubmed: 20946957
J Clin Gastroenterol. 2010 Apr;44(4):239-45
pubmed: 20216082
Int J Oncol. 2012 Jun;40(6):1733-47
pubmed: 22447316
J Immunol. 2010 Aug 15;185(4):2200-8
pubmed: 20639479
Nat Immunol. 2018 Mar;19(3):222-232
pubmed: 29379119
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Semin Liver Dis. 2019 Feb;39(1):26-42
pubmed: 30809789
ESMO Open. 2018 Dec 10;3(Suppl 1):e000455
pubmed: 30622744
Science. 2008 Oct 10;322(5899):271-5
pubmed: 18845758
Immunol Rev. 2000 Apr;174:21-34
pubmed: 10807504
EBioMedicine. 2019 Feb;40:457-470
pubmed: 30598371
Gut. 2015 May;64(5):842-8
pubmed: 25666193
J Hepatol. 2011 Apr;54(4):830-4
pubmed: 21145836
Hepatology. 2014 Nov;60(5):1776-82
pubmed: 24912948
Gut. 2014 May;63(5):844-55
pubmed: 24531850
World J Gastroenterol. 2019 Jun 28;25(24):2977-2989
pubmed: 31293335
J Leukoc Biol. 2013 Jul;94(1):25-39
pubmed: 23625198
PLoS One. 2020 Apr 2;15(4):e0231003
pubmed: 32240238
Eur J Immunol. 2016 Mar;46(3):513-22
pubmed: 26773716
Gastroenterology. 2007 Jun;132(7):2328-39
pubmed: 17570208
J Clin Med. 2019 Mar 19;8(3):
pubmed: 30893948
Cancer Lett. 2015 Jan 1;356(1):82-90
pubmed: 24125863
Cancer Res. 2005 Mar 15;65(6):2457-64
pubmed: 15781662
Cancers (Basel). 2018 Nov 08;10(11):
pubmed: 30413094
Annu Rev Immunol. 2018 Apr 26;36:247-277
pubmed: 29328785
Gastroenterology. 2017 Oct;153(4):1107-1119.e10
pubmed: 28648905
Cancer Treat Rev. 2015 Dec;41(10):868-76
pubmed: 26589760
Dig Dis. 2012;30(5):483-91
pubmed: 23108304
Hepatobiliary Surg Nutr. 2014 Dec;3(6):344-63
pubmed: 25568859
Cancers (Basel). 2019 Nov 20;11(12):
pubmed: 31756926
Curr Opin Immunol. 2016 Jun;40:36-42
pubmed: 26974478
Cancer. 2016 Feb 1;122(3):367-77
pubmed: 26540029
Trends Immunol. 2013 Sep;34(9):446-52
pubmed: 23668977
Hepatology. 2006 Feb;43(2 Suppl 1):S54-62
pubmed: 16447271
Clin Liver Dis (Hoboken). 2020 Mar 26;15(2):53-58
pubmed: 32226615
Dig Dis Sci. 2019 Apr;64(4):1030-1040
pubmed: 30830521
Gut. 2017 Feb;66(2):342-351
pubmed: 26669617
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
J Autoimmun. 2010 Feb;34(1):1-6
pubmed: 19717280
J Cancer. 2018 Aug 6;9(17):3187-3195
pubmed: 30210642
J Hepatol. 2015 Jun;62(6):1420-9
pubmed: 25733155
NPJ Precis Oncol. 2018 Feb 23;2(1):6
pubmed: 29872724
Oncologist. 2010;15 Suppl 4:14-22
pubmed: 21115577
Gene Expr. 2014;16(2):77-84
pubmed: 24801168
J Carcinog. 2017 May 29;16:1
pubmed: 28694740
Medicine (Baltimore). 2018 Dec;97(50):e13301
pubmed: 30557978
Gastroenterology. 2017 Mar;152(4):745-761
pubmed: 28043904
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Gastroenterology. 2013 Mar;144(3):512-27
pubmed: 23313965
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Clin Cancer Res. 2012 Dec 15;18(24):6580-7
pubmed: 23087408
Metabolism. 2017 Jul;72:94-108
pubmed: 28641788
Oncotarget. 2017 Sep 26;8(55):93644-93654
pubmed: 29212179
J Hepatol. 2013 Jul;59(1):81-8
pubmed: 23466307
Onco Targets Ther. 2016 Aug 02;9:4805-13
pubmed: 27536144
Nat Rev Gastroenterol Hepatol. 2016 Feb;13(2):88-110
pubmed: 26758786

Auteurs

Kumar Jayant (K)

Warwick Medical School, University of Warwick, Coventry CV4 7H, UK.
Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.

Nagy Habib (N)

Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.

Kai W Huang (KW)

Department of Surgery and Cancer, Imperial College London, London W12 0HS, UK.
Department of Surgery & Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan.
Centre of Mini-invasive Interventional Oncology, National Taiwan University Hospital, Taipei 100, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan.

Mauro Podda (M)

General, Emergency and Robotic Surgery Unit, San Francesco Hospital, 08100 Nuoro NU, Italy.

Jane Warwick (J)

Warwick Medical School, University of Warwick, Coventry CV4 7H, UK.

Ramesh Arasaradnam (R)

Warwick Medical School, University of Warwick, Coventry CV4 7H, UK.

Classifications MeSH